Surmodics (SRDX)
(Delayed Data from NSDQ)
$39.53 USD
-0.04 (-0.10%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $39.52 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
SRDX 39.53 -0.04(-0.10%)
Will SRDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRDX
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates
Take the Zacks Approach to Beat the Markets: Chewy, Pitney Bowes, 3M in Focus
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
Other News for SRDX
Top Merger Stocks Held By Fund Managers, Mid-Q3 2024
Hold Rating Maintained Amid SurModics Acquisition Delays and FTC Scrutiny
Surmodics merger deal draws FTC second request
Ronald B. Kalich Resigns from SurModics Board Amicably
SurModics Hold Rating Amidst Slowing Growth and Pending Acquisition Uncertainty